Guardian Pharmacy Services' (NYSE:GRDN - Get Free Report) lock-up period will expire on Tuesday, March 25th. Guardian Pharmacy Services had issued 8,000,000 shares in its public offering on September 26th. The total size of the offering was $112,000,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Guardian Pharmacy Services Trading Down 1.3 %
GRDN stock traded down $0.28 during midday trading on Friday, reaching $21.36. 73,072 shares of the company were exchanged, compared to its average volume of 154,034. Guardian Pharmacy Services has a 1-year low of $14.16 and a 1-year high of $25.74. The company's 50-day moving average price is $20.52.
Institutional Investors Weigh In On Guardian Pharmacy Services
Several institutional investors and hedge funds have recently made changes to their positions in GRDN. R Squared Ltd acquired a new stake in shares of Guardian Pharmacy Services during the 4th quarter worth about $30,000. Investment Research & Advisory Group Inc. acquired a new stake in shares of Guardian Pharmacy Services during the fourth quarter worth $34,000. BNP Paribas Financial Markets purchased a new stake in shares of Guardian Pharmacy Services in the fourth quarter valued at $37,000. Compass Financial Services Inc acquired a new position in Guardian Pharmacy Services in the fourth quarter valued at $58,000. Finally, JPMorgan Chase & Co. purchased a new position in Guardian Pharmacy Services during the fourth quarter worth about $77,000.
About Guardian Pharmacy Services
(
Get Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
Read More
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
